Links

Homepage

Stock List

Search by Ticker

News

Login

Incyte Corporation (NASDAQ:INCY)
Stock Analysis

INCY71.04
▼ -0.14%-0.1

Stock Analysis

The following stock analysis is based on 10.1 years of data (i.e. since Feb 08, 2013). All the stock history has been downloaded.

Stock Exchange

Incyte Corporation trades on the NasdaqGS exchange in USD dollars.

Sector

It is in the sector.

Current Status of Incyte Corporation

It is currently trading at $71.04 ($71.14 the previous day).

Financials

The next reporting date is in 32 days (2023 05 02).

CNN estimates profits for the upcoming quarter will be $0.54 per share ($849.5M). The current Canada / US exchange rate is 1.35539.



Over the past 12 months, $0 worth of shares have been purchased and $14210826 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is -3.8% per year assuming steady exponential growth. The actual 5 year average is -5.26. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year76.8137729729731+ Above Average
2 year76.033482142857-16.8- Below Average
3 year91.34992424242413.4+ Above Average
4 year80.5307095541412.8+ Above Average
5 year71.412965779468-36.7- Below Average
Incyte Corporation is projected by analysts to get to $89.50 within the next 12 months (26%), but preticted targets range from as high as $118.00 (66.1%) and as low as $61(-14.1%).

Risk

The worst drop it has had in recent years is -61.7%. It has a shape to the stock curve, which means

Stock shape test

DAYS AG0PRICE
1074.38DROPPING
3078.51DROPPING
6080.83DROPPING
15070.58RISING
36575.2DROPPING
80086.98DROPPING
120095.72DROPPING
160069.03RISING
2000112.8DROPPING
!!!!!!!!!!!! WARNING STOCK DROPPING !!!!!!!!!!!!!!!!!

The P/E value is 46.74.

Tradingview BuySell Widget

Yahoo News Feed

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

Wed, 29 Mar 2023 15:24:03 Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.... Read Full Article

Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan

Mon, 27 Mar 2023 16:27:04 Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.... Read Full Article

Company News for Mar 27, 2023

Mon, 27 Mar 2023 13:37:01 Companies in The News Are: SQ,INCY,JPM,WFC... Read Full Article

Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)

Mon, 27 Mar 2023 06:00:00 WILMINGTON, Del. and TOKYO, March 27, 2023--Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)... Read Full Article

Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'

Fri, 24 Mar 2023 17:28:37 The FDA issued a complete response letter (CRL) to Incyte Corporation (NASDAQ: INCY) ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use for certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD). The complete ...... Read Full Article

Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker

Fri, 24 Mar 2023 20:02:15 Incyte stock toppled Friday after the FDA unexpectedly rejected an extended-release version of its blockbuster drug, Jakafi.... Read Full Article

Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

Fri, 24 Mar 2023 11:14:11 The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.... Read Full Article

Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets

Fri, 24 Mar 2023 00:55:00 WILMINGTON, Del., March 24, 2023--Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets... Read Full Article

Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

Thu, 23 Mar 2023 17:51:05 Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.... Read Full Article

Incyte (INCY) Receives FDA Approval for Skin Cancer Treatment

Thu, 23 Mar 2023 16:14:04 Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.... Read Full Article

Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval

Thu, 23 Mar 2023 13:39:19 The FDA granted accelerated approval to Incyte Corporation's (NASDAQ: INCY) Zynyz (retifanlimab-dlwr) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Continued approval of Zynyz for this indication may be contingent on verification and description of ...... Read Full Article

UPDATE 2-US FDA grants accelerated approval for Incyte's skin cancer therapy

Wed, 22 Mar 2023 17:46:48 Incyte Corp said on Wednesday its monoclonal antibody, Zynyz, has won accelerated approval from the U.S. health regulator for treating a rare and aggressive type of skin cancer in adults. The U.S. Food and Drug Administration approved the ...... Read Full Article

Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

Wed, 22 Mar 2023 17:14:00 WILMINGTON, Del., March 22, 2023--Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)... Read Full Article

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

Tue, 21 Mar 2023 20:13:55 Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation. All while the global economic backdrop is marred by China and the Russia/Ukraine War. Therefore, investing ...... Read Full Article

Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II

Mon, 20 Mar 2023 15:32:03 Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.... Read Full Article

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Sat, 18 Mar 2023 19:40:00 WILMINGTON, Del., March 18, 2023--Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo... Read Full Article

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

Sat, 18 Mar 2023 14:40:00 WILMINGTON, Del., March 18, 2023--Long-term Extension Data from TRuE-V Program Demonstrate Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo... Read Full Article

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

Tue, 14 Mar 2023 22:30:00 WILMINGTON, Del., March 14, 2023--Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023... Read Full Article

Lab Notes: Fox Chase Cancer Center researcher gets $1M grant; NRx raises funds

Fri, 10 Mar 2023 16:34:50 Recent Philadelphia-area life sciences includes Aclaris and Incyte suffering setbacks with experimental therapies.... Read Full Article

Incyte (INCY) Down 8.3% Since Last Earnings Report: Can It Rebound?

Thu, 09 Mar 2023 16:30:04 Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.... Read Full Article
<